Conditions: Rheumatoid Arthritis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 52
Healthy volunteers: no

Brief summary:
This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in patients with active moderate to severe rheumatoid arthritis. Participants will receive a subcutaneous dose of tocilizumab 162 mg once weekly. The anticipated time on study treatment is 24 weeks.

Detailed description:

Arms:
arm 1: Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.

Interventions: intervention 1: Tocilizumab
Intervention descriptions: intervention 1: 162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks

Protocol document: